CClinicalTrials.gg
Status unknownNCT05752513Updated Mar 2, 2023

Early vs Late Bladder Dissection During CS Hysterectomy in Patients With PAS With Bladder Invasion

An interventional study of Late bladder dissection and early bladder dissection in Placenta Accreta Spectrum and Cesarean Hysterectomy, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-02.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Thirty-six singleton pregnant women with PAS and bladder invasion; total anterior or anterolateral invasion, who were scheduled for cesarean hysterectomy were randomly assigned into two equal groups

  • Group 1: included 18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta with or without ligation of anterior division of internal iliac artery before cesarean section.
  • Group 2: included 18 pregnant women scheduled for bladder last cesarean hysterectomy with or without ligation of anterior division of internal iliac artery.
02

Conditions studied

  • Placenta Accreta Spectrum
  • Cesarean Hysterectomy

Browse trials for

03

In context

Placenta Accreta

147 studies on the registry are indexed under Placenta Accreta; 39 are open to participants now.

This study's planned enrollment of 36 is below the median of 62 across 63 interventional studies indexed under Placenta Accreta.

Browse Placenta Accreta studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age: reproductive age.
  2. Pregnant with singleton living fetus.
  3. Previous one or more cesarean sections.
  4. Gestational age: > 34 weeks.
  5. Elective or non-emergency cesarean sections.
  6. Preoperative hemoglobin more than 9.5 gm/dl.

Exclusion criteria

Exclusion Criteria:

Women with history of any medical disorder with pregnancy eg. gestational diabetes, hypertension, or anemia.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Placebo comparator
    Group 1

    18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta

    Procedure: early bladder dissection

  • Experimental
    Group 2

    18 pregnant women scheduled for bladder last cesarean hysterectomy

    Procedure: Late bladder dissection

Interventions

  • ProcedureLate bladder dissection

    The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection

  • Procedureearly bladder dissection

    The bladder dissection is early as in classic cesarean hysterectomy

06

What researchers measure

Primary outcomes

  1. Amount of blood loss

    Time frame: during cesarean hysterectomy

Secondary outcomes

  1. Operative time

    Time frame: during cesarean hysterectomy

  2. bladder injury

    Time frame: during cesarean hysterectomy

  3. ureteric injury

    Time frame: during cesarean hysterectomy

  4. Need for massive blood transfusion

    Time frame: during cesarean hysterectomy

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05752513
Lead sponsor
Cairo University
Responsible party
Abdalla Mousa (Lecturer, Cairo University) — Principal investigator
First posted
Mar 2, 2023
Start date
Feb 23, 2023
Primary completion
May 1, 2023 (estimated)
Completion
May 1, 2023 (estimated)
Last update
Mar 2, 2023

Study contacts

Abdalla Mousa, Lecturer
Contact
Dr_abdallamousa@hotmail.com
01277664430

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion